BACKGROUND: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. METHODS: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers. RESULTS: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or >or=5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of >or=5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; >or=5 years: HR, 1.81; 95% CI, 0.75-4.36). CONCLUSION: This study does not support an association between statin use and breast cancer risk.
BACKGROUND: Mechanistic studies suggest that 3-hydroxy-3-methylglutaryl CoA inhibitors (statins) reduce the risk of breast cancer. Observational studies offer mixed results. METHODS: To evaluate the relation between statin use and breast cancer risk, we conducted a cohort study among women ages 45 to 89 years within an integrated health care delivery system. Information on statin use and covariates were obtained from automated databases. We identified breast cancer cases through the Surveillance, Epidemiology, and End Results registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for invasive breast cancer among statin users compared with nonusers. RESULTS: Among 92,788 women studied from 1990 to 2004, median follow-up time was 6.4 years, and 2,707 breast cancer cases were identified. During the study period, 7.4% of women used statins for at least 1 year, and the median duration of use was 3.1 years. We found no difference in breast cancer risk among statin users (HR, 1.07; 95% CI, 0.88-1.29) compared with nonusers. Risk of breast cancer did not differ by duration of use (1-2.9, 3-4.9, or >or=5 years) or hydrophobic statin use. We found a suggestive increased risk of breast cancer among statin users of >or=5 years (HR, 1.27; 95% CI, 0.89-1.81 for any statins and HR, 1.47; 95% CI, 0.89-2.44 for hydrophobic statins) and of estrogen receptor-negative tumors with increasing duration of statin use (1-2.9 years: HR, 1.33; 95% CI, 0.64-2.77; 3-4.9 years: HR, 1.68; 95% CI, 0.72-3.92; >or=5 years: HR, 1.81; 95% CI, 0.75-4.36). CONCLUSION: This study does not support an association between statin use and breast cancer risk.
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: Jane A Cauley; Anne McTiernan; Rebecca J Rodabough; Andrea LaCroix; Douglas C Bauer; Karen L Margolis; Electra D Paskett; Mara Z Vitolins; Curt D Furberg; Rowan T Chlebowski Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Patricia F Coogan; Lynn Rosenberg; Julie R Palmer; Brian L Strom; Ann G Zauber; Samuel Shapiro Journal: Epidemiology Date: 2002-05 Impact factor: 4.822
Authors: Stephan Woditschka; Laurel A Habel; Natalia Udaltsova; Gary D Friedman; Weiva Sieh Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-08-20 Impact factor: 4.254
Authors: Jessica Chubak; Rebecca Ziebell; Robert T Greenlee; Stacey Honda; Mark C Hornbrook; Mara Epstein; Larissa Nekhlyudov; Pamala A Pawloski; Debra P Ritzwoller; Nirupa R Ghai; Heather Spencer Feigelson; Heather A Clancy; V Paul Doria-Rose; Lawrence H Kushi Journal: Cancer Causes Control Date: 2016-09-17 Impact factor: 2.506
Authors: Heidi S Wirtz; Gregory S Calip; Diana S M Buist; Julie R Gralow; William E Barlow; Shelly Gray; Denise M Boudreau Journal: Am J Epidemiol Date: 2017-04-15 Impact factor: 4.897
Authors: Jean A McDougall; Kathleen E Malone; Janet R Daling; Kara L Cushing-Haugen; Peggy L Porter; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-05 Impact factor: 4.254
Authors: Leslie Spangler; Laura E Ichikawa; Rebecca A Hubbard; Belinda Operskalski; Andrea Z LaCroix; Susan M Ott; Delia Scholes Journal: Ann Epidemiol Date: 2014-10-16 Impact factor: 3.797
Authors: Signe Borgquist; Annika Jögi; Fredrik Pontén; Lisa Rydén; Donal J Brennan; Karin Jirström Journal: Breast Cancer Res Date: 2008-09-22 Impact factor: 6.466